Commit Biologics
Commit Biologics is developing the Bispecific Complement Engaging (BiCE) platform, a novel approach to activate the complement system for treating cancer and autoimmune diseases. The platform uses single domain antibodies to target and kill specific cells, leveraging the body's natural immune response. This modular system offers a highly targeted and effective method for therapeutic intervention.
Funding Round: Seed
Funding Amount: €21.5m
Date: 28-Jan-2025
Investors: Korys, Novo Holdings, Bioqube Ventures
Markets: Biotechnology, Pharmaceuticals, Immunotherapy, Life Science, Medical, Therapeutics
HQ: Aarhus, Middle Jutland, Denmark
Founded: 2021
Website: https://commitbio.com/
LinkedIn: https://www.linkedin.com/company/commit-biologics
Crunchbase: https://www.crunchbase.com/organization/commit-biologics
Leave a Comment
Comments
No comments yet.